Italy
Case Report
A Case Report on Metastatic Thyroid Carcinoma: Radiation-induced Bystander or Abscopal Effect?
Author(s): Slavisa Tubin, Franco Casamassima, Claudia Menichelli, Gabriella Pastore, Alessandro Fanelli and Rossana CrisciSlavisa Tubin, Franco Casamassima, Claudia Menichelli, Gabriella Pastore, Alessandro Fanelli and Rossana Crisci
Purpose: Both anti-CD20 antibodies (ibritumomab; ZEVALIN® and tositumomab; BEXXAR®) currently used for radioimmunotherapy of B cell non-Hodgkin’s lymphoma are murine immunoglobulins. The aim of this feasibility study was to evaluate the safety and efficacy of radioimmunotherapy with a human chimeric anti-CD20 antibody labelled with Yttrium-90 (90Y-rituximab) in patients with B cell lymphoma.
Methods: Patients with CD20+ B-cell lymphoma in partial remission or with progressive disease after at least one line of therapy were included. 90Y-rituximab was administered according to a similar schedule as currently approved by the European Medicines Agency for the treatment with 90Y-ibritumomab tiuxetan (ZEVALIN®): a first infusion of rituximab 250 mg/m² is repeated one week later and directly followed by.. Read More»
DOI:
10.4172/1948-5956.1000175
Cancer Science & Therapy received 3968 citations as per Google Scholar report